Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan + Chemotherapy in Platinum-Resistant Ovarian Cancer
NCT06815497Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telmisartan in ovarian cancer. Primary endpoint: Progression-Free Survival at 48 months. Started Jan 2026; status: recruiting.
02
Drugs
telmisartan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06815497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06815497.